bioLytical INSTI HIV – 1/HIV-2 Antibody Test

The Florida Department of Health's Bureau of Communicable Disease, HIV/AIDS Section is seeking to procure bioLytical INSTI HIV-1/HIV-2 antibody testing devices through a single-source purchase authorization in accordance with Chapter 60A-1.045 of the Florida Administrative Code. The procurement is being conducted by the state of Florida on behalf of Leon County and encompasses FDA-approved, third-generation INSTI IgG/IgM testing devices that deliver diagnostic results within 60 seconds, along with associated testing kit training services. These rapid point-of-care testing devices are intended for deployment in at-risk communities to support HIV screening and diagnostic initiatives. The key objective is to acquire specialized testing technology that meets the Department's specific requirements for quick, reliable HIV detection in community health settings. The procurement was posted on April 2, 2026, with a submission deadline of April 23, 2026. The single-source procurement methodology indicates that bioLytical has been identified as the sole qualified vendor capable of meeting the Department's specialized testing requirements, thereby eliminating competitive bidding procedures.

The single-source procurement approach restricts this opportunity to bioLytical, as the vendor has been designated as the sole source capable of providing the required INSTI HIV testing technology and associated training. The authorization document does not specify set-aside designations, disadvantaged enterprise restrictions, or other limitations on responding organizations, though the single-source determination effectively limits the procurement to the identified vendor. No incumbent vendors or current contractors are referenced in the available documentation, nor are there specifications regarding required integration with existing infrastructure or technology systems. The purchase authorization document itself does not detail specific contract values, budget ranges, quantities, contract terms, or renewal options, as it serves as the foundational approval framework rather than the final procurement contract specification. Interested parties seeking additional procurement details, pricing information, or clarification on requirements should contact the Florida Department of Health's Bureau of Communicable Disease prior to the April 23, 2026 deadline.